Vertex Pharmaceuticals Incorpor
Stocks
PACCAR Inc.
Stocks
Vertex Pharmaceuticals vs PACCAR Inc: Which Stock Offers Better Value for Money?
Last updated: June 6, 2026
Summary
Vertex Pharmaceuticals exhibits a higher earnings per share and profit margin, indicating strong profitability in the biotech sector. PACCAR offers a more attractive dividend yield and a lower price-to-earnings ratio, making it appealing for income-focused investors. This comparison highlights the distinct value propositions of each company within their respective industries, aiding investors in making informed decisions based on value for money.
Key Differences at a Glance
| Aspect | Vertex Pharmaceuticals Incorpor | PACCAR Inc. | Winner |
|---|---|---|---|
| Earnings Per Share (EPS) | 16.83 | 4.7 | Vertex Pharmaceuticals Incorpor |
| Price-to-Earnings (PE) Ratio | 26.55 | 24.83 | Tie |
| Dividend Yield | null | 1.19% | PACCAR Inc. |
| Market Capitalization | USD 113.41 billion | USD 61.41 billion | Vertex Pharmaceuticals Incorpor |
| Profit Margin | 35.51% | 8.91% | Vertex Pharmaceuticals Incorpor |
Earnings Per Share (EPS): Vertex Pharmaceuticals' EPS of 16.83 significantly outperforms PACCAR's EPS of 4.7, indicating higher profitability per share and better value generation relative to its stock price.
Price-to-Earnings (PE) Ratio: Both companies have similar PE ratios, with Vertex slightly higher, suggesting comparable valuation multiples in their respective sectors, making PE ratio less decisive in valuation comparison here.
Dividend Yield: PACCAR's dividend yield of 1.19% offers immediate income for investors, whereas Vertex does not pay dividends, positioning PACCAR as more attractive for income-focused investors seeking value for money through dividends.
Market Capitalization: Vertex's market cap is nearly double PACCAR's, indicating a larger, potentially more stable company with stronger investor confidence, translating into perceived value for growth-oriented investors.
Profit Margin: Vertex's profit margin of 35.51% vastly outweighs PACCAR's 8.91%, demonstrating superior profit efficiency, which translates to better value for shareholders in terms of profitability.
Detailed Analysis
Vertex Pharmaceuticals stands out in this comparison due to its high earnings per share (EPS) of 16.83, which is over three times higher than PACCAR's EPS of 4.7. This indicates that Vertex generates significantly more profit per share, reflecting a more efficient utilization of its revenue stream. Additionally, Vertex's profit margin of 35.51% far exceeds PACCAR's 8.91%, revealing superior cost control and higher profitability in the biotech industry. Such high margins underscore Vertex's strong value proposition for investors seeking biotech stocks with robust profit efficiency.
Conversely, PACCAR's dividend yield of 1.19% provides immediate income, making it appealing for income-focused investors. While its PE ratio of approximately 24.83 is slightly lower than Vertex's 26.55, both are within a similar valuation multiple range, suggesting comparable investor expectations on earnings growth. PACCAR's lower market capitalization of USD 61.41 billion compared to Vertex's USD 113.41 billion indicates a smaller company size, which may translate to higher growth potential but also higher risk.
From a valuation perspective, Vertex's higher market cap and profitability margins suggest it offers greater value for growth-oriented investors willing to accept a higher stock price relative to earnings. Meanwhile, PACCAR's stable dividend yield and lower valuation multiple make it attractive for value investors seeking income and steady returns. The beta values also indicate low volatility for Vertex (0.31) and near-market volatility for PACCAR (0.992), which can influence risk-adjusted returns.
Overall, Vertex Pharmaceuticals provides a compelling value-for-money proposition through its superior profitability, larger market cap, and earnings quality, ideal for investors prioritizing growth and efficiency. PACCAR, on the other hand, offers relative stability and income, making it suitable for value and income investors seeking steady cash flow and discounted valuation metrics.
Verdict
Vertex Pharmaceuticals offers better value for growth-oriented investors due to its higher EPS, profit margin, and market cap, which reflect superior profitability and scale. However, PACCAR provides better value for income-focused investors with its dividend yield and lower valuation multiple. In conclusion, if the priority is high profitability and growth potential, Vertex is the clear winner; for steady income and lower valuation risk, PACCAR offers more value for money.
Who Should Choose What
Choose Vertex Pharmaceuticals Incorpor if...
Investors seeking high-growth biotech stocks with superior profitability, large market capitalization, and strong profit margins. Suitable for those aiming for long-term capital appreciation with high value-for-money in the healthcare sector.
Choose PACCAR Inc. if...
Investors looking for stable industrial stocks with dividend income, lower valuation multiples, and moderate growth prospects. Ideal for income-focused investors seeking value for money in the heavy machinery industry.